First topical gene therapy treatment for dystrophic epidermolysis bullosa

View source ↗

Summary

The European Medicines Agency approved Vyjuvek as the first topical gene therapy for dystrophic epidermolysis bullosa, an ultra-rare genetic skin disorder. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa

Drugs mentioned

• Vyjuvek

Snippet

Vyjuvek expected to bring substantial therapeutic benefits and improve quality of life for patients with ultra-rare genetic skin disorder